Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Walter Morton who wrote (790)	8/13/1997 7:40:00 PM
From: scaram(o)uche	of 2742

I know of several in the reagents area. Endogen would be an example. Some others may have been discussed in this thread. Take a look at the manner that management has grown Biosource International, starting with the acquisition of Tago. Consolidation is sorely needed in the reagents business, and is a good route to rapid growth. However, CIST management has indicated a desire to go with diagnostics/therapeutics, and they licensed IL-1beta to an OEM supplier. The addition of the ex-Unimed CEO to the Board might be best considered as further indication that they plan to take a non-reagents route. Should be very interesting. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next